Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03919955
Other study ID # 2019P000666
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date September 3, 2019
Est. completion date October 20, 2023

Study information

Verified date October 2023
Source Brigham and Women's Hospital
Contact Scott A Sands, PhD
Phone 6172780911
Email sasands@bwh.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A pharmacological, non-mechanical therapy for OSA that is efficacious and tolerable remains elusive. Here the investigators study the effect on sleep apnea severity of a combination of pharmacological agents (atomoxetine and oxybutynin, "AtoOxy") over a 1 month period of time. The current study will answer the following questions: Does ongoing, repeated-dose administration of atomoxetine-plus-oxybutynin (referred to as "AtoOxy") improve OSA severity, and do patients exhibit signs of symptomatic relief? Most importantly, which phenotypic subgroup of patients preferentially benefit from this intervention?


Description:

Aim 1 - Effect of AtoOxy on sleep apnea severity. In a randomized controlled double-blind crossover study, 48 patients with moderate-to-severe OSA will take atomoxetine-plus-oxybutynin ("AtoOxy") versus placebo nightly for 1 month, with a 2-week washout in between. The investigators will test the hypothesis that AtoOxy reduces the Apnea-hypopnea index (primary outcome measure), and improves the following secondary outcomes: - Nocturnal oxygenation, per "hypoxic burden of sleep apnea" - Frequency of arousals from sleep (Arousal index) - Self-reported sleepiness (Epworth Sleepiness Scale) - Disease-specific quality of life (Functional Outcomes of Sleep Questionnaire, Short Form). - Disease-specific quality of life (Sleep Apnea Quality of Life Index, Short Form) Additional pre-specified exploratory outcome measures will be assessed, including Visual Analog Scales (Sleep Quality, Treatment Satisfaction) and additional polysomnographic measures of sleep (Stage 1 sleep, %total sleep time). Adherence and adverse events will also be carefully monitored to assess repeated-dose tolerance of the intervention. Aim 2 - Determine which patient phenotypes respond best to AtoOxy. Patients will also take part in an additional night before initiating study medication to measure the key mechanisms causing OSA. The investigators will prospectively test the hypothesis that greater pharyngeal collapsibility determines a reduced response to therapy. They will also separately test the hypotheses that a reduced muscle responsiveness, reduced baseline muscle activation, a higher arousal threshold, and a lower loop gain will facilitate a greater response to therapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 75
Est. completion date October 20, 2023
Est. primary completion date October 20, 2023
Accepts healthy volunteers No
Gender All
Age group 21 Years to 70 Years
Eligibility Inclusion criteria: - Ages 21-70 years - Diagnosed OSA or clinically-suspected OSA - Not using CPAP (>1 month). Exclusion criteria: - Any uncontrolled medical condition - Current use of the medications under investigation - Use of medications expected to stimulate or depress respiration (including opioids, barbiturates, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid). - Current use of hypnotic medications (trazodone, eszopiclone, benzodiazepines). - Current use of SNRIs/SSRIs or anticholinergic medications. - Conditions likely to affect obstructive sleep apnea physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition. - Respiratory disorders other than sleep disordered breathing: chronic hypoventilation/hypoxemia (awake SaO2 < 92% by oximetry) due to chronic obstructive pulmonary disease or other respiratory conditions. - Other sleep disorders: periodic limb movements (periodic limb movement arousal index > 10/hr), narcolepsy, or parasomnias. - Contraindications for atomoxetine and oxybutynin, including: - hypersensitivity to study drugs (angioedema or urticaria) - pheochromocytoma - use of monoamine oxidase inhibitors - benign prostatic hypertrophy, urinary retention - untreated narrow angle glaucoma - bipolar disorder, mania, psychosis - history of major depressive disorder (age<24). - history of attempted suicide or suicidal ideation within one year prior to screening - clinically significant constipation, gastric retention - pre-existing seizure disorders - clinically-significant kidney disorders (eGFR<60 ml/min/1.73m2) - clinically-significant liver disorders - clinically-significant cardiovascular conditions - severe hypertension (SBP>180 mmHg or DBP>110 mmHg measured at baseline) - cardiomyopathy (LVEF<50%) or heart failure - advanced atherosclerosis - history of cerebrovascular events - history of cardiac arrhythmias e.g., atrial fibrillation, QT prolongation - other serious cardiac conditions that would raise the consequences of an increase in blood pressure or heart rate - myasthenia gravis - pregnancy/breast-feeding - Allergy to lidocaine (Aim 2 only) - Claustrophobia - Pregnancy or nursing

Study Design


Intervention

Drug:
Atomoxetine
Atomoxetine 80 mg, per mouth, before bed
Oxybutynin
Oxybutynin 5 mg, per mouth, before bed
Placebo
Placebo, per mouth, before bed

Locations

Country Name City State
United States Brigham and Women's Hospital Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Brigham and Women's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Apnea-hypopnea index [AHI] Apneas and hypopneas per hour (3% desat and/or arousal), % change from baseline one month
Secondary Hypoxic Burden Desaturation area under curve × event frequency one month
Secondary Arousal index Scored EEG arousals per hour (>3 s), % change from baseline one month
Secondary Epworth Sleepiness Scale Self-reported sleepiness on scale of 0-24, higher being more sleepy one month
Secondary Functional Outcomes of Sleep Questionnaire, Short Form Disease-specific quality of life one month
Secondary Sleep Apnea Quality of Life Index, Short Form Disease-specific quality of life one month
See also
  Status Clinical Trial Phase
Completed NCT05582070 - Effect on Sleep of Surgical Treatment of Severe Nasal Obstruction N/A
Completed NCT03927547 - Sleep Disordered Breathing and Cardiopulmonary Disease in Peruvian Highlanders N/A
Recruiting NCT04007380 - Psychosocial, Cognitive, and Behavioral Consequences of Sleep-disordered Breathing After SCI N/A
Completed NCT02188498 - Electrocardiography Data Analysis in Sleep Disorders
Completed NCT01503164 - Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism N/A
Recruiting NCT00747890 - Surgical Treatment of Mild Obstructive Sleep Apnea N/A
Active, not recruiting NCT00738179 - Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea to Prevent Cardiovascular Disease Phase 3
Completed NCT00841906 - Alice PDx User/Validation Extended Trial N/A
Completed NCT00202501 - Usefulness of Nasal Continuous Positive Airway Pressure (CPAP) Treatment in Patients With a First Ever Stroke and Sleep Apnea Syndrome N/A
Completed NCT00047463 - Effects of Treating Obstructive Sleep Apnea in Epilepsy Phase 2
Not yet recruiting NCT06029881 - Portable System for Non-intrusive Monitoring of Sleep
Recruiting NCT06093347 - Central Apnoea Monitor Study
Terminated NCT05445869 - Severe OSA Study (SOS) N/A
Withdrawn NCT04096261 - The Importance of Sleep Quality and the Blood-brain Barrier in Cognitive Disorders and Alzheimer's Disease
Recruiting NCT04575740 - Phenotyping Mechanistic Pathways for Adverse Health Outcomes in Sleep Apnea N/A
Completed NCT04676191 - Validation of a Contactless Vital Signs Measurement Sensor N/A
Recruiting NCT06015620 - Comorbidities Resolution After MGB Surgery and Change in Body Composition
Completed NCT06051097 - Metabolic Syndrome and Obstructive Sleep Apnea
Completed NCT05687097 - Untreated Sleep Apnea as an Aggravating Factor for Other Secondary Medical Conditions After Spinal Cord Injury
Recruiting NCT05197855 - Sleep Quality Evolution: Dreem Under CPAP N/A